SNDX - Syndax Pharmaceuticals GAAP EPS of -$0.59 beats by $0.01

2023-05-08 16:13:37 ET

• Syndax Pharmaceuticals press release ( NASDAQ: SNDX ): Q1 GAAP EPS of -$0.59 beats by $0.01 .

• As of March 31, 2023, Syndax had cash, cash equivalents, short- and long-term investments of $449.0 million and 69.6 million common shares and prefunded warrants outstanding.

  First quarter 2023 research and development expenses increased to $34.1 million from $30.0 million for the comparable prior year period.

• First quarter 2023 general and administrative expenses increased to $12.0 million from $6.8 million for the comparable prior year period.

• For the second quarter of 2023, the Company expects research and development expenses to be $38 to $43 million andtotal operating expenses to be $53 to $58 million.

• For the full year of 2023, the Company continues to expect research and development expenses to be $160 to $175 million and total operating expenses to be $225 to $240 million.

For further details see: